Argenx
ARGX
#468
Rank
NZ$90.16 B
Marketcap
NZ$1,443
Share price
2.50%
Change (1 day)
45.19%
Change (1 year)
Argenx is a Dutch company that develops antibody therapies to fight autoimmune diseases and cancer.

EPS for Argenx (ARGX)

EPS in 2025 (TTM): NZ$15.24

According to Argenx 's latest financial reports the company's current EPS (TTM) is NZ$15.07. In 2024 the company made an earnings per share (EPS) of NZ$23.65 an increase over its 2023 EPS that were of NZ-$8.77.

EPS history for Argenx from 2011 to 2025

Annual EPS

Year EPS Change
2025 (TTM)NZ$15.24-35.57%
2024NZ$23.65-369.77%
2023NZ-$8.77-60.46%
2022NZ-$22.1763.33%
2021NZ-$13.58-40.37%
2020NZ-$22.77183.47%
2019NZ-$8.03123.09%
2018NZ-$3.6054.93%
2017NZ-$2.3214.07%
2016NZ-$2.0413.05%
2015NZ-$1.80-36.34%
2014NZ-$2.83209.04%
2013NZ-$0.92-33.99%
2012NZ-$1.39185.59%
2011NZ-$0.49